title: Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model.
abstract: OBJECTIVE
  To assess whether T1 relaxation time of tumors may be used to assess response to bevacizumab anti-angiogenic therapy.
  
  
  METHODS
  12 female nude mice bearing subcutaneous SKOV3ip1-LC ovarian tumors were administered bevacizumab (6.25ug/g, n=6) or PBS (control, n=6) therapy twice a week for two weeks. T1 maps of tumors were generated before, two days, and 2 weeks after initiating therapy. Tumor weight was assessed by MR and at necropsy. Histology for microvessel density, proliferation, and apoptosis was performed.
  
  
  RESULTS
  Bevacizumab treatment resulted in tumor growth inhibition (p<0.04, n=6), confirming therapeutic efficacy. Tumor T1 relaxation times increased in bevacizumab treated mice 2 days and 2 weeks after initiating therapy (p<.05, n=6). Microvessel density decreased 59% and cell proliferation (Ki67+) decreased 50% in the bevacizumab treatment group (p<.001, n=6), but not apoptosis.
  
  
  CONCLUSIONS
  Findings suggest that increased tumor T1 relaxation time is associated with response to bevacizumab therapy in ovarian cancer model and might serve as an early indicator of response.
authors.affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Murali K
authors.initials: MK
authors.lastname: Ravoori
authors.affiliation: Department of Obstetrics and Gynecology, The University of Tokushima Graduate School, Tokushima, Japan.
authors.forename: Masato
authors.initials: M
authors.lastname: Nishimura
authors.affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Sheela P
authors.initials: SP
authors.lastname: Singh
authors.affiliation: Department of Gynecologic Oncology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Chunhua
authors.initials: C
authors.lastname: Lu
authors.affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Lin
authors.initials: L
authors.lastname: Han
authors.affiliation: Department of Biostatistics, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Brian P
authors.initials: BP
authors.lastname: Hobbs
authors.affiliation: Department of Gynecologic Oncology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Sunila
authors.initials: S
authors.lastname: Pradeep
authors.affiliation: Department of Gynecologic Oncology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Hyun J
authors.initials: HJ
authors.lastname: Choi
authors.affiliation: Department of Imaging Physics, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: James A
authors.initials: JA
authors.lastname: Bankson
authors.affiliation: Department of Gynecologic Oncology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America; Department of Cancer Biology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America; Center for RNA Interference and Non-Coding RNA, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Anil K
authors.initials: AK
authors.lastname: Sood
authors.affiliation: Department of Cancer Systems Imaging, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America; Department of Radiology, U.T.- M.D. Anderson Cancer Center, Houston, Texas, United States of America.
authors.forename: Vikas
authors.initials: V
authors.lastname: Kundra
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000818:Animals; D017209:Apoptosis; D000068258:Bevacizumab / Q000627:therapeutic use*; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D051379:Mice; D008819:Mice, Nude; D055806:Microvessels / Q000473:pathology; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000628:therapy; D010051:Ovarian Neoplasms / Q000098:blood supply / Q000473:pathology / Q000628:therapy*; D023041:Xenograft Model Antitumor Assays
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab